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Abstract: Epilepsy contributes to approximately 1% of the global disease burden. By affecting 
especially young children as well as older persons of all social and racial variety, epilepsy is a 
present disorder worldwide. Currently, only 65% of epileptic patients can be successfully treated 
with antiepileptic drugs. For this reason, alternative medicine receives more attention. Cannabis has 
been cultivated for over 6000 years to treat pain and insomnia and used since the 19th century to 
suppress epileptic seizures. The two best described phytocannabinoids, (−)-trans-Δ9-
tetrahydrocannabinol (THC) and cannabidiol (CBD) are claimed to have positive effects on different 
neurological as well as neurodegenerative diseases, including epilepsy. There are different 
cannabinoids which act through different types of receptors and channels, including the 
cannabinoid receptor 1 and 2 (CB1, CB2), G protein-coupled receptor 55 (GPR55) and 18 (GPR18), 
opioid receptor µ and δ, transient receptor potential vanilloid type 1 (TRPV1) and 2 (TRPV2), type 
A γ-aminobutyric acid receptor (GABAAR) and voltage-gated sodium channels (VGSC). The 
mechanisms and importance of the interaction between phytocannabinoids and their different sites 
of action regarding epileptic seizures and their clinical value are described in this review. 
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1. Introduction 
Epilepsy is a chronic neurological disease affecting approximately 50 million people of all ages 
and sexes worldwide. This spectrum disorder not only impairs neuronal circuits, but also leads to 
social burden and severe morbidity showing highest incidence in young children and the elderly [1]. 
Epileptic seizures are defined as paroxysmal electrical discharges originated from various brain 
regions, leading to molecular, physiological, cognitive and social dysfunction [2]. The origin is 
thought to lie in the imbalance of the activation of excitatory and inhibitory synapses due to several 
causes, including genetic disorders, stroke, infections, injuries etc. According to the International 
League Against Epilepsy (ILAE), seizures can be classified in two groups: focal (or partial) and 
generalized. Focal seizures initiate in small groups of neurons in one hemisphere of the brain, or of 
one lobe, resulting in jerks and clonic movements. Generalized seizures involve both hemispheres 
from the onset and might lead to tonic-clonic movements and loss of consciousness and posture. 
Furthermore, epilepsy can be split into primary and secondary epilepsy. Primary epilepsy is of 
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unknown cause without any previous physiological or molecular damage of the brain, whereas 
secondary epilepsy might occur as a result of neurological etiologies including those structural, 
genetic, infectious, metabolic, or immune [3,4]. 
Epileptic seizures can be caused by an imbalance of inhibitory and excitatory activity as shown 
by drugs able to block inhibitory type A y-aminobutyric acid receptor (GABAAR) and the 
corresponding synaptic currents [5], or by activating ligand-gated and voltage-gated excitatory 
synaptic currents [6,7]. Thus, seizures might be limited by an increase of inhibitory currents [8] or 
decrease of excitatory currents [9,10]. However, in recent years many researchers have investigated 
this disease, but the exact mechanisms and ultimate cure still remains to be elucidated. 
With the notable exception of absence seizures, anticonvulsants used for different epilepsy types 
act by enhancing inhibitory drive or by counteracting excitatory activity. Antiepileptic drugs (AEDs) 
have been used as a successful treatment for approximately 65% of suffering patients [11]. For 
instance, lorazepam and other benzodiazepines increase GABAAR-mediated inhibition and thus 
display a decent medication for symptomatic seizures [12,13]. Other medications such as phenytoin 
and carbamazepine prevent voltage-gated Na+ channels from activation and therefore reduce the 
firing of action potentials [14,15]. Nevertheless, these first-line medications are linked to strong-side 
effects and tolerability. In 1886, the first surgical approach for epilepsy was done by Horsley Victor, 
which expanded the therapeutic possibilities for epileptic seizures. He resected cortical tissue 
adjacent to a depressed skull fracture and healed a patient suffering from focal motor seizures [16]. 
Nowadays, for 35% of drug-resistant patients with refractory epilepsy, invasive treatments including 
surgical resection or neurostimulation have been demonstrated to be the only chance for cure. Thus, 
invasive treatments often appear as the ultimate prospect for these patients. 
In the last years, the need for therapies for refractory seizures has largely arisen, which lead 
researchers to expand their mind to investigate more in alternative eligible treatments. In recent 
studies phytocannabinoids have been tested as an alternative approach for patients suffering from 
refractory seizures. 
2. Cannabis sativa L. and Its Major Derivatives 
Cannabis sativa L. has shown its medical potential for more than 6000 years, during which it 
spread from Northwestern Asia to Europe and finally to all over the world. The first historical 
evidence of medicinal use of C. sativa was recorded in the herbal medicine Pên-ts’ao Ching described 
by the Emperor Shen Nung around 2000 BC [17]. Furthermore, in ancient Greece and Rome the plant 
was used to treat pain, spasm and cramps [18]. The genus Cannabis belongs to the family of 
Cannabaceae. The taxonomy proposed by Small and Cronquist combining morphological and 
chemical description, considered Cannabis as monospecific (Cannabis sativa L.) with two subspecies 
(Cannabis sativa L. subsp. sativa, and Cannabis sativa L. subsp. indica) and four varieties (Cannabis sativa 
L. subsp. sativa var. sativa; Cannabis sativa L. subsp. sativa var. spontanea; Cannabis sativa L. subsp. indica 
var. indica; Cannabis sativa L. subsp. indica var. kafiristanica) [19]. Cannabis contains a characteristic 
class of isoprenylated resorcinyl polyketides compounds called phytocannabinoids to distinguish 
them from synthetic and endogenous cannabinoids. Notwithstanding phytocannabinoids are more 
characteristic of Cannabis, there are reports in the literature that phytocannabinoids also occur in 
other plants such as Helichrysum [20]. One hundred and fifty phytocannabinoids have been recorded 
for C. sativa to date and can be classified into 11 general types: (−)-trans-Δ9-tetrahydrocannabinol 
(THC), (−)-trans-Δ8-tetrahydrocannabinol (Δ8-THC), cannabigerol (CBG), cannabichromene (CBC), 
cannabidiol (CBD), cannabinodiol (CBND), cannabielsoin (CBE), cannabicyclol (CBL), cannabinol 
(CBN), cannabitriol (CBT), and miscellaneous types [20]. THC and CBD are the most important and 
studied plant cannabinoids. In 1940, CBD was first isolated from the plant [21]. In 1963 its structure 
was first described [22] and followed by its first identification as a crystal structure in 1977 [23]. The 
major breakthrough in cannabinoid research was achieved by Mechoulam and Gaoni in 1964 with 
the identification of the chemical structure of the first described psychoactive phytocannabinoid THC 
[24]. Cannabis varieties can be classified into five different chemotypes depending on the 
concentration of the main phytocannabinnoids. Drug-type cannabis varieties that have a high 
Pharmaceuticals 2020, 13, 174 3 of 22 
 
THC/CBD ratio (≫1.0) are classified as chemotype I; varieties with an intermediate ratio (0.5–2.0) are 
classified as chemotype II; fiber-type varieties that have a low THC/CBD ratio (≪1.0) are classified as 
chemotype III; chemotype IV are cannabis varieties that contain CBG as the main cannabinoid; and 
chemotype V cannabis fiber-type varieties that contain almost no cannabinoids [25]. 
Although CBD and THC have long been considered authentic natural products of cannabis, 
these molecules are not enzymatically synthesized in the plant, which instead produces cannabidiolic 
acid (CBDA) and tetrahydrocannabinolic acid (THCA) (Figure 1). 
 
Figure 1. Biosynthetic pathway of major phytocannabinoids. 
Today it is accepted that CBD and THC are an unnatural artifact of the corresponding acid 
precursors CBDA and THCA, produced via a temperature-catalyzed reaction. The different 
phytocannabinoids in plants originate from a common precursor, which is cannabigerolic acid 
(CBGA), in turn obtained by the alkylation of olivetolic acid with geranyl pyrophosphate (Figure 1) 
[26,27]. The other phytocannabinoids are biosynthesized from CBGA by the action of oxidoreductase 
enzymes, such as THCA-synthase, CBDA-synthase and cannabicromenic acid (CBCA)-synthase, 
which lead to the formation of phytocannabinoids such as THCA, CBDA and CBCA [28]. These 
carboxylated cannabinoids, so-called “acids”, are easily decarboxylated into the corresponding 
“neutral” derivatives, such as THC, CBD and CBC, with a non-enzymatic reaction of decarboxylation 
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catalyzed by heat [29]. There are also different phytocannabinoids resulting from oxidation or 
isomerization of THC and CBD, such as CBN or Δ8-THC. 
THC is the main phytocannabinoid of cannabis which is responsible for the psychoactive 
properties such as psychotropic effects, including euphoria, appetite enhancement and alteration of 
sensory perception. Since the chemical structure of THC was elucidated by Mechoulam in 1964, a 
large number of scientific papers have been published concerning its mechanism of action. 
Furthermore, its structure was taken as a lead compound for the development of increasingly active 
synthetic cannabinoids. Such synthetic cannabinoids have different chemical structures like classical 
(e.g., nabilones) [30], non-classical (e.g., WIN55212-2) [31], aminoalkylindoles (e.g., JWH-018) [32] 
and endogenous arachidonic acid derivatives including endocannabinoids such as 2-
arachidonoylglycerol (2-AG) and N-arachidonylethanolamide (AEA [33–35]. THC does not only 
exhibit positive effects in the treatment of severe pain and nausea [36] but was also shown to inhibit 
T-cell immune-response, as well as to diminish inflammatory cytokine and chemokine release in rat 
microglia [37]. However, the use of cannabis is associated with abuse potential leading to behavioral 
changes and psychological impairment, because of the pharmacological properties of THC [38,39]. 
Therefore, THC is still not considered as a reliable, predictable and safe long-term derivative to treat 
neurological diseases such as epilepsy or depression [40]. Alternatively, to THC, CBD represents a 
promising tool against refractory epilepsy as it lacks the psychoactive properties and presents few 
side effects. A reduced occurrence of seizure discharges in rats has been demonstrated in the 
hippocampus treated with CBD [41]. It has been shown that CBD exerts beneficial effects to restore 
the activity of hippocampal neurons [42] and prevents neuronal cell death in temporal lobe epilepsy 
(TLE) models [43]. It is furthermore observed that CBD, as THC, shows high anti-inflammatory [44], 
antioxidant, and anticonvulsant activity [45,46]. The cannabis-derived product Epidiolex® (GW 
Pharmaceuticals, Cambridge, UK) was approved in 2018 by the US Food and Drug Administration 
(FDA) for the treatment of the rare pediatric onset refractory epilepsy disorders Dravet syndrome 
(DS) and Lennox-Gastaut syndrome (LGS) [47]. Currently, Epidiolex®, which is composed of 100 
mg/mL of CBD in sesame oil, has been tested in clinical trials with children, obtaining a 36.5% median 
reduction in monthly motor seizures during a 12-week treatment period. Adjunctive CBD could even 
raise the number to approximately 50% of seizure reduction during a total of 96-weeks. Even though 
this open-labeled study observed very few side effects (5%) and promising outcomes, one should be 
reminiscent about the placebo effect of this medication associated with parental expectation and 
media attention put on the children. Children, which moved across the US country to receive the 
treatment were twice as likely to decrease seizure events/month compared to children who happened 
to be living in the area of the medical center (47% versus 22%) [48,49]. 
Until now over 150 compounds of Cannabis sativa could be identified as phytocannabinoids of 
which a few numbers have already been tested to reveal healing properties (Figure 2). Δ9-
tetrahydrocannabutol (Δ9-THCB), which is the butyl homologue of THC showed possible anti-
inflammatory and analgesic activity in a model of acute inflammatory pain [50]. As THC, Δ8-THC 
presents psychoactive effects and in the first experiments promisingly diminished the growth of lung 
adenocarcinoma both in vitro and in vivo [51,52]. The propyl analogue of THC, Δ9-
tetrahydrocannabivarin (THCV) is an antioxidant [53] and shows symptom-relieving and 
neuroprotective effects in animal models of Parkinson’s disease [54]. As well as the propyl analogue 
of CBD named cannabidivarin (CBDV) offers medical advantages: CBDV is able to rescue motor 
impairment, cognitive dysfunction and brain atrophy in a mouse model of Rett syndrome [55]. 
Further compounds of the cannabis plant, which count to the most abundant cannabinoids are CBG 
and CBC: several studies observed that both CBG and CBC could be used against neuroinflammation, 
oxidative stress and exhibit analgesic effects [56–60]. As CBD, CBN has been detected to have many 
valuable responses against inflammation [61], convulsions [62] and pain [63]. The structures of the 
phytocannabinoids are presented in Figure 2. 
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Figure 2. Structures of nine phytocannabinoids showing anticonvulsant activity; Δ9-
tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabutol (Δ9-
THCB), Δ9-tetrahydrocannabivarin (THCV), cannabidiol (CBD), cannabidivarin (CBDV), 
cannabichromene (CBC), cannabinol (CBN), cannabigerol (CBG). 
There are still many cannabinoids which have been isolated and described in the last years, but 
still remain to be experimentally explored. 
3. A Brief Summary of the Endocannabinoid System (ECS) 
The ECS is a key modulatory system involving the cannabinoid receptor 1 (CB1) and 2 (CB2), 
their endogenous ligands and the enzymes responsible for their biosynthesis and inactivation. It has 
been suggested that the ECS plays an important role in the neuroprotection of acute neurological 
diseases, such as epilepsy, as well as chronic neurodegenerative diseases such as Parkinson’s disease 
[64,65]. 
The discovery of CB1 and CB2 receptors in the central nervous system (CNS) opened the field for 
the exploration of endogenous regulating systems and compounds associated with physiological 
processes and neurological disorders involving the endocannabinoids. CB1 is mostly sited on 
presynaptic inputs in several parts of the brain, including the olfactory bulb, the cerebral cortex and 
corpus striatum, and is highly expressed also in the hippocampus. In the dentate gyrus and CA3 
hippocampal subfield, especially in the stratum oriens, highly dense receptor binding sites have been 
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observed [66]. Conversely, CB2 receptors are mainly expressed in cells of the immune and 
hematopoietic system, but they have been previously discovered in neurons of the brain stem [67]. 
In 1992, the first endogenous ligand of CB1 was described and named anandamide (i.e., AEA) [34]. 
Three years later, 2-AG also was identified [33]; both are described as the most abundant endogenous 
ligands for CB1 and CB2. Anandamide primarily targets CB1, while 2-AG shows agonistic effects on 
both CB1 and CB2 receptors [68]. Anandamide and 2-AG are important mediators of synaptic 
plasticity and are synthesized by the lipid precursors N-arachidonoyl phosphatidylethanolamine 
(NAPE) and diacylglycerol (DAG) in the cell membrane [69]. They are released “on demand” by 
physiological or pathological stimuli and act as retrograde messengers [70]. Their signaling pathway 
also may be initiated by the depolarization of a postsynaptic neuron, which opens voltage-gated 
calcium channels (VDCCs) leading to increased cytoplasmic calcium so to trigger endocannabinoid 
synthesis and release from the postsynaptic cell by a yet unknown mechanism. Endocannabinoids 
diffuse retrogradely to a presynaptic bouton and bind to receptors reducing the likelihood of release 
of the excitatory and inhibitory neurotransmitters [71,72]. Anandamide is hydrolyzed to arachidonic 
acid (AA) and ethanolamine by fatty acid amide hydrolase (FAAH), while 2-AG is hydrolyzed to AA 
and glycerol by monoacylglycerol lipase [73,74]. Both these endocannabinoids have been found to 
play a significant role in the regulation of excitatory synapses suggesting the impairment of 
endocannabinoid signaling being linked to epilepsy. It has been described that CB1 and diacylglycerol 
lipase α are downregulated in epileptic human hippocampi [75]. The extracellular accumulation of 
2-AG or anandamide was related to an anticonvulsant effect in the rat model of pentylenetetrazole-
induced tonic-clonic seizures [76]. Additionally, in patients suffering from TLE lower concentrations 
of anandamide were found in the cerebrospinal fluid [77]. Therefore, inhibition of the breakdown of 
2-AG and especially anandamide has been investigated lately as a new pharmaceutical target against 
epileptic seizures. The FAAH inhibitor URB597 was able to prevent or diminish alterations evoked 
by seizures in a kainic acid mouse model of TLE [78]. According to a study on cocaine-induced 
seizures in mice, URB597 inhibited seizure activity and showed a neuroprotective activity against 
seizure-related cell death [79]. However, the mechanism and function of inhibition of 
endocannabinoid hydrolysis in epileptogenesis requires further investigation. 
4. Anticonvulsant Effects of Phytocannabinoids on Diverse Targets 
The use of cannabis in neurological and neurodegenerative disorders is controversial and, thus, 
still under consideration. THC and CBD have shown in numerous preclinical studies to diminish 
epileptic seizures, thus increasing their medical interest. They are able to regulate the excitability of 
neuronal circuits involving the ECS and associated ligands and receptors. CBD has been proved to 
act as a reuptake inhibitor of anandamide, changing the excitatory and inhibitory dynamics of 
synapses [80]. The fact that phytocannabinoids not only exhibit agonist and antagonist actions leads 
to the understanding that the wide range of targets could reveal opposing and unpredictable effects. 
Therefore, the major exploration to specify the pharmacological targets of cannabinoids is crucial for 
the development of medicines for specific disorders. The promising beneficial health effects 
encourages many researchers in testing the possible therapeutic properties on seizures using 
phytocannabinoids with a chemical structure similar to THC and to CBD, such as Δ8-THC, Δ9-THCB, 
Δ9-THCV, CBDV, CBN. The anticonvulsant properties of cannabinoids acting through different 
receptors and channels are depicted and visualized (Figure 3) as follows. 
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Figure 3. Schematic overview of the action of different phytocannabinoids possibly able to modulate 
seizures and epilepsy. Cannabidiol (CBD) inhibits the synthesis and mobilization of N-
arachidonoylethanolamide (AEA) from the postsynaptic synapses, therefore acting in an independent 
and indirect antagonist manner with respect to the cannabinoid receptors CB1 and CB2. CBD 
antagonizes the activity of G protein-coupled receptor 18 (GPR18) and 55 (GPR55) and Na+ influx of 
voltage-gated sodium channels (VGSC) to block neurotransmission activity. Abnormal-CBD (Abn-
CBD) acts through GPR18 to decrease intracellular Ca2+ release (left side). CBD and CBDV are 
proposed to show positive modulation and agonist effects on the type A γ-aminobutyric acid receptor 
(GABAAR), leading to an activation of GABA mobilization on inhibitory synapses. CBD and 
cannabidivarin (CBDV) activate and desensitize the transient receptor potential vanilloid type 1 and 
2 (TRPV1/2), reducing extracellular Ca2+ influx and decreasing Ca2+ concentration. (−)-trans-Δ9-
tetrahydrocannabinol (THC) and CBD are allosteric modulators of the opioid receptor type µ and δ, 
which inhibits the release of neurotransmitters to activate the glutamatergic N-methyl-D-aspartate 
(NMDA) receptor leading to a seizure reduction. THC activates CB1 and CB2 leading to an inhibition 
of glutamate release. This action can be blocked by CBD, which is able to inhibit THC-CB1 interaction. 
Δ9-tetrahydrocannabivarin (THCV) is suggested to induce anticonvulsant activity in a concentration- 
and CB1-mediated manner. The exact mechanisms of activation, inhibition or modulation are still 
under consideration. Furthermore, the different potency of the indicated molecules should be taken 
into account to correctly interpreter the illustrated effects, as in the case of THC and CBD which bind 
to CB receptors with affinity, respectively, in the nM and mM range. 
4.1.G protein-Coupled Receptors 
4.1.1. Cannabinoid Receptors CB1 & CB2 
In 1991, the cannabinoid receptor CB1 was first described in the brain by receptor 
autoradiography and was identified as a G protein-coupled receptor [81,82]. The majority of CB1 
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receptors are located on presynaptic boutons of GABAergic interneurons [83,84], but can also be 
found in glutamatergic synapses [85]. Their main task is to reduce the likelihood of neurotransmitter 
release through various mechanisms, such as inhibition of calcium influx and adenylyl cyclase 
activity, or activation of the presynaptic potassium channels [86]. CB1 receptors are the most 
abundant receptors in the human and murine brain, including the olfactory bulb, hippocampus, 
amygdala, cerebellum, neocortex and basal ganglia, but are also found in peripheral tissues and cells 
[66,87]. Sequence analysis showed that CB1 sequence identity of humans and mice matches 97%, 
indicating the mouse as a reliable model for researching the CB1 receptor [88]. In 2005, CB2 receptors 
were first observed in the CNS, but their density is much lower than CB1 and they are mainly located 
on microglia and specific neurons [67,89,90]. CB2 receptors are primarily found in hematopoietic and 
immune cells including B-cells, T-cells and macrophages [91], having their major task in regulating 
the cytokine release [92]. CB1 and CB2 are the main targets of the endogenous ligands anandamide 
and 2-AG; whereas anandamide mainly binds CB1, 2-AG shows agonist effects on both receptors [68]. 
Interestingly, a small number of phytocannabinoids have demonstrated to possess seizure-
diminishing effects acting through both CB1 and CB2 receptors. 
CBD is suspected to act also by interacting with targets different from CB1 and CB2 receptors, 
suggesting the involvement of alternative transduction mechanisms [93–95]. Due to the inhibition of 
breakdown of anandamide, CBD may have an indirect mechanism to reveal its anticonvulsant 
activity [80]. Moreover, CBD has even shown to have CB1/CB2 antagonist properties and appears to 
decrease the THC-CB1 agonist activity in vitro [95]. However, the precise mechanism of the efficacy 
of CBD signaling is not fully understood yet. Similarly, CB1 antagonist effects of Δ9-THCV were 
observed, while high concentration appeared to be agonistic in a model of antinociception [93,96]. 
Other data showed that Δ9-THCV exerts antiepileptic and anticonvulsant activities, suggesting a CB1-
mediated effect [97]. CB1 and CB2 represent important but not exclusive agonistic targets for the 
compounds Δ8-THC and THC, whereas CB1 plays the major role for psychoactivity [98]. There have 
been many controversial studies about the effects of THC on seizure activity: some studies have 
shown anticonvulsant properties of THC in maximal electroshock rat model, while in other 
experiments the opposite effect of THC was observed, initiating seizures in Fischer rats and B6C3F1 
mice [99,100]. It was also reported that both Δ8-THC and THC significantly reduced the incidence of 
seizures on the first and second day of a 7-day administration in cobalt-epileptic rats [101]. CBN is 
another cannabinoid, which has shown its effectiveness to reduce seizures in a mouse model of 
maximal electroshock [102]. As a full agonist for both cannabinoid receptors, as well as inverse 
agonist for CB2 (depending on the concentration), it has though not been proven if the anticonvulsant 
effects of CBN depend on one of the cannabinoid receptors or rely on other targeting [98,103]. Both 
phytocannabinoids (CBG and CBC) are partial CB1/CB2 agonists, but with no anticonvulsant effects 
[104,105]. 
4.1.2. G Protein-coupled Receptor 55 (GPR55) 
The orphan receptor GPR55, which was identified in 1999, is expressed in regions of the CNS, 
including the caudate-putamen, and peripheral tissue such as the intestines, spleen and adrenals. 
This receptor is also located in the hippocampus, in particular the dentate gyrus excitatory neurons 
where it is suggested to be a regulator of spatial learning and memory, and synaptic plasticity. The 
rat GPR55 is composed of 319 amino acids that share an amino acid identity of 67% with the human 
GPR55 [106,107]. This putative cannabinoid receptor is involved in anti-inflammatory effects in 
microglial cells, and proliferation of pancreatic cells and tumor growth in mice [108,109]. GPR55 
activates intracellular Ca2+ release in neurons, which can alter neuronal excitability by stimulating 
glutamate release [110]. For this reason, antagonist activity could result in the shift of excitatory and 
inhibitory balance. Notably, CBD was shown to increase inhibitory transmission by blocking GPR55, 
which leads to an attenuation of epileptic seizures as seen in a mouse model of DS, a severe form of 
childhood epilepsy [111]. GPR55 antagonism has been evaluated in several studies as a potential 
treatment for refractory epilepsy. Besides, it has been observed that THC, Δ9-THCV, CBD, CBDV and 
CBG are able to block the response generated by the main endogenous GPR55 ligand 
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lysophosphatidylinositol (LPI) and endocannabinoids [110,112]. However, THC and Δ9-THCV, 
which are partial and weak GPR55 agonists, might act through different targets and, for this reason, 
they could involve a variety of mechanisms. 
4.1.3. G Protein-coupled Receptor 18 (GPR18) 
Discovered in 1997, GPR18 is, as GPR55, described as putative and orphan cannabinoid receptor 
and was shortly considered to be named CBX and CB3 receptor, respectively. Due to some missing 
criteria of the Nomenclature Committee of the International Union of Basic and Clinical 
Pharmacology (IUPHAR), these receptors were officially declared as orphan cannabinoid receptors 
[113,114]. In the mouse, GPR18 is located in a broad range of tissues including the cardiovascular 
system and the gastrointestinal tract, where it is involved in obesity/diabetes-associated 
inflammation and lymphoid system regulation. In humans, this receptor has not been as well studied 
as in rodents, but shows expression in the brainstem, hypothalamus, testis, spleen and lymph nodes 
[114–117]. GPR18 is composed of 331 amino acids and overlaps in amino acid identity with a 
similarity of 86% (mouse) and 85% (rat) to humans [118]. The downstream signaling of GPR18 is 
activated by N-arachidonoyl glycine (NAGly), which is a mixed agonist/antagonist endogenous 
ligand shown to activate intracellular Ca2+ mobilization [119]. The receptor is found on the cell surface 
of macrophages and microglial cells, as well as intracellularly, so to modulate the downstream 
signaling [120–122]. There is evidence that it plays a vital role in apoptosis of inflammatory leukocytes 
and is engaged in the reduction of intraocular pressure in mice [123,124]. As a GPR18 antagonist, 
CBD inhibits NAGly and was suggested to lower the effects of excitation to restrain the action 
potential firing. Abnormal cannabidiol (Abn-CBD) is a synthetic regioisomer of CBD, since it has the 
same functional group on a different position. It is a selective ligand and agonist for GPR18 able to 
induce a reduction in calcium release [125]. The selective and concentration-dependent ligand THC 
is able to induce proconvulsant effects by activating the calcium mobilization and, therefore, 
excitation by activating GPR18. Moreover, CBD was able to block the effects of THC in a simultaneous 
treatment. The evidence for the ability of CBD and THC to regulate the activity of GPR18 is still poor 
and does not allow a clear interpretation; however, there is a strong interest for the possible 
therapeutic use of these molecules [120]. 
4.1.4. Opioid Receptor µ and δ 
Opioid receptors are membrane receptors located in multiple regions of the CNS, including 
various hypothalamic nuclei, amygdala, hippocampus, substantia nigra, dorsal root ganglia, spinal 
cord, etc.; they are also peripherally found, as in the gastrointestinal apparatus [126]. Due to their 
broad range of involvement in numerous neurological modulations, such as mood disorders, pain 
perception and drug abuse, opioid receptors are widely explored [127–129]. THC and CBD might act 
as allosteric modulators of the opioid receptor subtypes µ and δ [130]. Antagonists of selective δ 
receptors were shown to diminish N-methyl-D-aspartate (NMDA) receptor-mediated seizures in 
vivo [131]. CBD revealed in multiple studies beneficial effects on massive uncontrolled glutamatergic 
firing, especially mediated by NMDA receptors. A study in 2018 proposed that CBD may act either 
by an unknown mechanism or as antagonist-like agent towards δ receptors to reduce NMDA 
receptor-induced seizures in vivo [132]. 
4.2. Transient Receptor Potential Vanilloid 
In 2001, phytocannabinoids were first observed to interact and modulate the transient receptor 
potential vanilloid (TRPV) type 1 and 2 [133]. TRPV represents a subtype of the transient receptor 
potential channel (TRP), consisting of six transmembrane helices, a cation-permeable pore with 
intracellular N- and C-termini, allowing a calcium influx into the cell. TRPV1 (capsaicin-sensitive) 
and TRPV2 (capsaicin-insensitive) are widely located on distinct dorsal root ganglia neurons, 
trigeminal ganglia, peripheral afferent fibers and especially on nociceptive sensory endings, where 
they transduce pain, temperature, proinflammatory stimuli, and can be also activated by chemical 
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substances, such as anandamide, vanilloids and cannabinoids [134]. As TRPV1 agonists, CBD rapidly 
dephosphorylates and desensitizes TRPV1 channels leading to a decrease in calcium influx and 
therefore reduced neurotransmission. There is evidence that TRVP1 channels are overexpressed in 
models of TLE and patients suffering from epilepsy [135]. Consistent with these observations, CBD 
presented reduced anticonvulsant properties in TRPV1 knock-out mice [136]. Patch-clamp analyses 
performed in HEK293 cells revealed that CBD and CBDV activated and desensitized TRPV1 and 
TRPV2 in a dose-dependent manner. In addition, CBDV was able to significantly decrease the 
amplitude and duration of epileptiform neuronal spikes [137]. In a model for juvenile seizures, CBDV 
was able to suppress seizures induced by pentylenetetrazole at postnatal day 10 (P10) in rats. 
Otherwise, in P20 rats CBDV decreased seizures induced by pentylenetetrazole or methyl-6,7-
dimethoxyl-4-ethyl-β-carboline-3-carboxylate administration, and also by maximal electroshock 
stimulation, in agreement with the results obtained in P20 TRPV1 knockout mice with the same drug. 
These findings show that the effects of CBDV in different ages and epilepsy models are TRPV1-
dependent [138]. Other phytocannabinoids including CBN, CBG, CBC and Δ9-THCV show TRPV 
type 1-4 agonistic activity, but a correlation to epileptic behavior has not yet been found [139,140]. 
These results will lead to further basic research on targeting TRPV1 and TRPV2 to test their promising 
potential in clinical treatment of epilepsy. 
4.3. GABAA Receptors 
The GABAAR was first detected in the brain in 1950 and is a member of the pentameric ligand-
gated ion channels superfamily [141]. To date, there are 19 different subunits present in the 
mammalian brain: six α (α1–6), three β (β1–3), three γ (γ1–3), and δ, ϵ, θ, π and ρ1 to ρ3, which form 
the heteromeric GABAA receptors providing a wide spectrum of pharmacological and physiological 
characteristics [142]. When GABA, which mediates the main inhibitory neurotransmission in the 
brain and spinal cord, binds to GABAAR, the rapid influx of Cl− is activated resulting in 
hyperpolarization and inhibition of the cell [143,144]. Those currents can be regulated by several 
positive and negative allosteric modulators such as benzodiazepine, neurosteroids, zinc and 
phytocannabinoids. The composition of the subunits of GABAAR is responsible for the sensitivity to 
those modulators, meaning that a shift in subunit composition could alter the functioning of GABAAR 
and lead to unexpected neuronal impairment [145]. GABAA receptors are expressed on synaptic and 
extrasynaptic sites of the most, if not all, neurons in the CNS and were previously found to be also 
located on human peripheral blood mononuclear cells (PBMC) [146]. They are considered as being 
the most crucial receptors for pharmacological and physiological alteration and contribute to the 
etiology of numerous neurological and mental diseases such as epilepsy, schizophrenia and 
Angelman’s syndrome [147–149]. Multiple studies proved that a change of GABAAR subunit 
composition occurred in a model of kainic acid induced TLE, as well as in hippocampal tissues from 
patients affected with TLE [147,150,151]. At a concentration of 100 µM, CBD acts as a positive 
allosteric modulator of GABAAR as showed by voltage clamp electrophysiological measurements in 
Xenopus oocytes. Interestingly, coadministration of CBD and clobazam resulted in a greater 
anticonvulsant potency than clobazam only, because it significantly enhanced GABAAR-mediated 
transmission in a mouse model of DS [152,153]. An additional study examined patients with DS who 
donated their brain tissue to be transplanted in Xenopus oocytes to prove that a low dose of CBD was 
able to significantly enhance GABAA currents [154]. CBDV is yet an unknown GABAAR agonist but 
demonstrated in a similar preclinical study for TLE its anticonvulsant properties mediated by 
GABAAR. TLE tissue with hippocampal sclerosis was derived from pharmaco-resistant TLE patients 
and showed, after a prolonged incubation with CBDV, a recovery of the current rundown of GABAAR 
[155]. However, there is still little evidence about the anticonvulsant effects of CBDV mediated by 
GABAAR. 
4.4. Voltage-Gated Sodium Channel (VGSC) 
VGSC (NaVs) were discovered by Hodgkin and Huxley in 1952, when examining the excitation 
and conductance in axons of giant squids and were first isolated from the eel electroplax [156,157]. 
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They are members of the cation channel superfamily and are responsible for the Na+ conduction 
through the cell plasma membrane. Mammalian VGSC are composed of a large pore-forming α-unit 
that associates with one or two β subunits and have been found in almost every type of neuron 
examined. VGSC subunit α has nine known subtypes, which show tissue specific expression 
properties. The subtypes Nav1.1, Nav1.2 and Nav1.3 are primarily located in the CNS and peripheral 
neurons, whereas the other members are expressed in skeletal, cardiac muscles and interstitial cells 
of Cajal [158]. Mutation in the gene SNC1A, which encodes Nav1.1 results in cognitive impairment 
and causes due to the deficient sodium channel shift in neuronal excitability, resulting in phenotypes 
known as generalized epilepsy with febrile seizures. Furthermore, this mutation—occasionally in 
combination with GABAAR impairment—is carried by the majority (70–80%) of patients with DS 
[159,160]. Further mutations in Nav1.1, Nav1.2, Nav1.3 and Nav1.6 have been linked to the occurrence 
of epileptic seizure in patients of all ages [161–163]. Acting as an agonist, CBD appeared to inhibit 
and block the opening of Nav1.1 to Nav1.7 with low µM potencies, measured in human cell culture 
and rat brain slices [104]. In a Hodgkin-Huxley model of cortical neuron, CBD could decrease and 
stabilize neuronal excitability [164]. A different study showed that CBD was able to preferentially 
target and inhibit aberrant and increased resurgent currents in mutations in Nav1.6. Moreover, CBD 
demonstrated to diminish overall action potential firing of murine striatal neurons, assuming the 
high potential of treating drug-resistant children affected from DS who carry gene mutations in VGSC 
with CBD [165]. 
5. Isolated Phytocannabinoid versus Cannabis Extract: the “Entourage” Effect 
The application of individual phytocannabinoids isolated from cannabis extract in therapy has 
recently sparked widespread debate [166], in spite that Mechoulam elucidated the structure of THC 
in 1964 and a drug based on the stereoisomer produced by cannabis, THC (Dronabinol), was 
approved by the FDA as safe and effective drug for HIV/AIDS-induced anorexia and chemotherapy-
induced nausea and vomiting [167]. This is because the employment of cannabis or its medicinal 
extracts is still widespread, since anecdotal evidence indicates that cannabis extracts are more potent 
and with less side effects than THC itself. Several recent works indicate that other components of the 
cannabis extract may somehow interact with THC [166,168–171]. Studies in humans and animals 
suggest high potential for CBD to attenuate the effects of THC, in particular in decreasing the effects 
of THC on cognition/memory [172–174]. Conversely, there are preclinical studies that indicate that 
CBD may potentiate some effects of THC [165,175–180]. However, the few studies about the CBD-
THC interaction represent a profound lack of research respecting the manner how CBD may affect 
behavioral and physiological effects of THC. 
As THC, CBD was also formulated as a single active substance drug [181]. But also, in this case 
the use of hemp (cannabis for fiber of chemotype III) extract is widely considered for both 
nutraceutical and medicinal purposes. A recent study proposes that hemp extract requires a dose of 
CBD four times less than the drug containing the single CBD molecule to achieve the same 
therapeutic effect [182]. In this article it is clearly indicated how the use of hemp extract leads to a 
lower incidence of the adverse effects observed when administering the purified CBD. E. Russo refers 
to this synergy as an “entourage” effect [166]. The main problem with the use of hemp extracts is the 
poor knowledge of the entire chemical composition. Over 500 compounds and over 200 terpenes have 
been identified in cannabis so far [183]. Each of these compounds could be present in the hemp extract 
and could influence the pharmacological activity of CBD. Furthermore, the non-compliance of strict 
rules of drug preparation, could lead to high concentrations of THC in the extract with side effects 
typical of the latter compound. 
It is challenging to identify the absolute chemical composition of the hemp extract even if, thanks 
to recent sophisticated analytical techniques, it is possible to determine a large quantity of substances 
present even at very low concentrations. 
In conclusion, the use of CBD extract certainly offers advantages over isolated CBD, but it 
becomes difficult, if not impossible, to standardize it for each of its chemical components with 
consequent variability in pharmacological action. 
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6. Conclusions 
For thousands of years the cannabis plant has represented a significant medical and economic 
value and is used all over the world. With the first preclinical experiments solely using selected 
compounds widened the enormous impact on alternative treatments for neurological diseases. 
Cannabis sativa L. stepped in the main focus of present research and reached an approximately 2400-
fold publication rate since the first official cannabis report in 1939. While the first experimental 
approaches of THC and CBD have revealed possible beneficial health effects in general, previous 
studies focus more on distinct targets as well as signaling cascades in diverse models of specific 
diseases. Therefore, more and more derivatives of the plant were isolated and tested on a molecular 
and behavioral level, leading to the knowledge that most phytocannabinoids act through a broad 
spectrum of targets, which complicates the understanding of their exact pathway and action. THC 
and CBD have shown in numerous preclinical studies to diminish duration, severity and incidence 
of epileptic seizures in combination with remote adverse effects. With the approval of the first 
cannabis-derived medical drug in 2018, Epidiolex® has fought its way from the laboratory to patients 
of all ages suffering from refractory epilepsy depicting a high success rate. The severe forms of 
pharmaco-resistant childhood epilepsy, DS and LGS respond to Epidiolex® with a 36–50% 
amelioration rate; a milestone in epilepsy research [68,184]. Even though the anticonvulsant efficacy 
of different phytocannabinoids including CBD, THC, Δ8-THC, Δ9-THCB, Δ9-THCV, CBDV, CBN have 
been proven, the precise mechanism and modulation of targets depicted in this review opens many 
questions. Most phytocannabinoids are not only restricted to the modulation of a single receptor, but 
rather have the ability to regulate various receptors and channels and might therefore change the 
entire circuitry. In the past years, researchers have identified further targets of cannabinoids such as 
serotonin receptor (5HT1A, 5HT2A, 5HT3A), GPR12, glycine receptor, acetylcholine receptor, 
peroxisome proliferator-activated receptors, α2 adrenergic receptor, equilibrative nucleoside 
transporter and VGCCs. Until now there is no evidence that cannabinoids have beneficial effects on 
epilepsy acting through those receptors or channels and still remain to be examined. 
Recently, two new compounds have been first isolated from the cannabis plant: the butyl and 
heptyl homologs of THC: Δ9-THCB and Δ9-THCP, respectively. Regarding their characteristics 
showing high CB1 affinity and overall high cannabimimetic activity, those new derivatives represent 
promising tools in the research of neurological diseases and especially epilepsy, which needs to be 
established in future studies [50,185]. 
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